Bevacizumab
- CAS No.
- 216974-75-3
- Chemical Name:
- Bevacizumab
- Synonyms
- Avastin;Avastatin;Rhumab-vegf;Bevacizumab;Bevacituzumab;Unii-2S9zzm9Q9v;Bevacizumab Impurity;Bevacizumab 25mg/ml;Bevacizumab (Avastin);Bevacizumab USP/EP/BP
- CBNumber:
- CB3966244
- Molecular Formula:
- C6638H10160N1720O2108S44
- Molecular Weight:
- 0
- MDL Number:
- MFCD08272721
- MOL File:
- Mol file
- MSDS File:
- SDS
- TDS File:
- TDS
| Product description | Number | Pack Size | Price |
| USP mAb 002, Monoclonal IgG1 United States Pharmacopeia (USP) Reference Standard | 1445547 | 2MG | $1480 |
| Bevacizumab - 25mg/ml solution in PBS | FB76708 | 1mg | $301.98 |
| Bevacizumab - 25mg/ml solution in PBS | FB76708 | 2mg | $402.62 |
| Bevacizumab - 25mg/ml solution in PBS | FB76708 | 5mg | $823.55 |
| Bevacizumab - 25mg/ml solution in PBS | FB76708 | 10mg | $1464.1 |
| More product size | |||
| storage temp. | Store at -80°C |
|---|---|
| solubility | Soluble in DMSO |
| form | Liquid |
| color | Colorless to light yellow |
| NCI Dictionary of Cancer Terms | Avastin; bevacizumab |
| FDA UNII | 2S9ZZM9Q9V |
| NCI Drug Dictionary | Avastin |
| ATC code | L01XC07 |
| Proposition 65 List | Bevacizumab |
| UNSPSC Code | 41116107 |
| NACRES | NA.24 |
SAFETY
Risk and Safety Statements
| Hazardous Substances Data | 216974-75-3(Hazardous Substances Data) |
|---|
Bevacizumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich | 1445547 | USP mAb 002, Monoclonal IgG1 United States Pharmacopeia (USP) Reference Standard | 216974-75-3 | 2MG | $1480 | 2026-04-30 | Buy |
| Biosynth | FB76708 | Bevacizumab - 25mg/ml solution in PBS | 216974-75-3 | 1mg | $301.98 | 2026-06-04 | Buy |
| Biosynth | FB76708 | Bevacizumab - 25mg/ml solution in PBS | 216974-75-3 | 2mg | $402.62 | 2026-06-04 | Buy |
| Biosynth | FB76708 | Bevacizumab - 25mg/ml solution in PBS | 216974-75-3 | 5mg | $823.55 | 2026-06-04 | Buy |
| Biosynth | FB76708 | Bevacizumab - 25mg/ml solution in PBS | 216974-75-3 | 10mg | $1464.1 | 2026-06-04 | Buy |
Bevacizumab Chemical Properties,Uses,Production
Description
Bevacizumab, a humanized IgG1 monoclonal antibody against vascular endothelial growth factor (VEGF), inhibits tumor angiogenesis and delays disease progression. It was launched in the US as an intravenous infusion for the treatment of metastatic colorectal cancer in combination with fluorouracil-based chemotherapy. Bevacizumab was developed by engineering the VEGF binding residues of the murine neutralizing antibody A.4.6.1 into the framework of the consensus human IgG1. Its amino acid sequence is approximately 93% human IgG and 7% murine antibody and is produced in a CHO cell expression system. Bevacizumab binds VEGF with high affinity (Kd=0.5 nM) and prevents its interaction with tyrosine kinase receptors VEGFR1 and VEGFR2 on the surface of endothelial cells, thereby inhibiting cell proliferation and microvascular growth. In mouse models, administration of bevacizumab blocked the growth of human tumor xenografts and reduced the size and number of metastases. The recommended dosage of bevacizumab is 5 mg/kg administered once every 2 weeks as an intravenous infusion until disease progression is detected. Based on a population pharmacokinetic analysis of patients who received 1–20 mg/kg of bevacizumab once every 1–3 weeks, the estimated half-life was approximately 20 days, and the predicted time to reach steady state was 100 days. The maximum and minimum steady-state serum concentrations at 2.5 mg/kg/week dose were 226 and 88 μg/mL, respectively. Clearance of bevacizumab is low, and varies with body weight, gender and tumor burden. In patients with colorectal cancer receiving bevacizumab 5–10 mg/kg in combination with fluorouracil and leucovorin, mean total clearance was 2.79 ml/kg/day. In clinical studies involving the administration of bevacizumab (5 mg/kg every 2 weeks) or placebo in addition to bolus-IFL (irinotecan 125 mg/m2 i.v., 5-fluorouracil 500 mg/ m2 i.v., and leucovorin 20 mg/m2 i.v. administered once weekly for four weeks every six weeks), the median overall survival was significantly increased from 15.6 months in the bolus IFL + placebo arm to 20.3 months in the bolus IFL + bevacizumab arm. Similar increases were also seen in progression-free survival (6.4 versus 10.6 months), overall response rate (35% versus 45%), and duration of response (7.1 months versus 10.4 months). The most common adverse events in these trials were hypertension, diarrhea and leucopenia. Other clinically significant adverse events reported occasionally were gastrointestinal perforations, thromboembolic events, bleeding and proteinuria. Because wound healing may be impaired by inhibition of VEGF, bevacizumab therapy is not recommended until 28 days after primary surgery.
Originator
Genentech (US)
History
Bevacizumab (Brand name: Avastin, developed by Genentech, Inc.) was first approved by the FDA on February 26, 2004, for the treatment of metastatic colorectal cancer. Subsequently, Avastin, alone or in combination with other anticancer drugs, was approved for the treatment of lung cancer, brain cancer (glioblastoma), kidney cancer, metastatic cervical cancer, platinum-resistant recurrent ovarian cancer, metastatic non-squamous non-small cell lung cancer, and hepatocellular carcinoma. On February 25, 2008, the FDA granted accelerated approval to Avastin in combination with paclitaxel chemotherapy for first-line treatment of advanced HER2-negative breast cancer. However, on November 18, 2011, the FDA withdrew Avastin's indication for breast cancer treatment. As of October 13, 2021, the FDA approved Merck's Keytruda (penzizumab) in combination with chemotherapy, whether or not it is combined with bevacizumab, as a treatment for patients with persistent, recurrent, or metastatic cervical cancer expressing PD-L1 (CPS ≥1).
brand name
Avastin
Clinical Use
Monoclonal antibody:
Treatment of colorectal cancer
Treatment of breast cancer
Treatment of renal cell carcinoma
Treatment of lung cancer
Treatment of ovarian, fallopian tube or peritoneal
cancer
Enzyme inhibitor
This humanized monoclonal antibody (MW = 149.2 kDa; CAS 216974-75- 3), known by the tradename Avastinò, is an angiogenesis inhibitor that targets vascular endothelial growth factor A (VEGF-A). Because VEGF is the key angiogenic factor in tumors, blocking VEGF signal transduction can lead to tumor growth arrest and inhibition of metastasis. The rationale for Avastin therapy is premised on findings that high VEGF expression correlates with (a) reduced overall survival, (b) disease progression, (c) greater risk of relapse, (d) lymph node involvement, and (e) malignant pleural effusion. By binding directly bind to VEGF-A, Avastin blocks its interaction with endothelial cell VEGF receptors, thereby inhibiting neovascularization and depriving cancer cells of vital nutrients and oxygen. Avastin is approved for: metastatic colorectal cancer (mCRC), when started with the first or second intravenous 5-FU–based chemotherapy for metastatic cancer; advanced-stage nonsquamous, non–small cell lung cancer (NSCLC), when administered in combination with carboplatin and paclitaxel in patients who have not received chemotherapy for their advanced disease; metastatic renal cell cancer (mRCC) when used with interferon-a; and glioblastoma multiforme (GBM) in adult patients whose cancer has progressed after prior treatment.
target
Angiogenesis is important for tumour growth and metastasis, and is an important target for new biological agents. Bevacizumab is a humanised recombinant antibody that prevents vascular endothelial growth factor (VEGF) receptor binding, and inhibits angiogenesis and tumour growth.
Drug interactions
Potentially hazardous interactions with other drugs
Bisphosphonates: increased risk of osteonecrosis of
the jaw.
Cytotoxics: avoid with panitumumab.
Vaccines: risk of generalised infections with live
vaccines - avoid.
Metabolism
Assessment of bevacizumab metabolism in rabbits following a single IV dose of 125I-bevacizumab indicated that its metabolic profile was similar to that expected for a native IgG molecule which does not bind VEGF. The metabolism and elimination of bevacizumab is similar to endogenous IgG i.e. primarily via proteolytic catabolism throughout the body, including endothelial cells, and does not rely primarily on elimination through the kidneys and liver. Binding of the IgG to the FcRn receptor results in protection from cellular metabolism and the long terminal half-life.
Bevacizumab Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai Minbiotech Co., Ltd. | +8617315815539 | sales@minbiotech.com | CHINA | 129 | 58 |
| Biochempartner | 0086-13720134139 | candy@biochempartner.com | CHINA | 965 | 58 |
| Shenzhen Nexconn Pharmatechs Ltd | +86-755-89396905 +86-15013857715 | admin@nexconn.com | China | 10403 | 58 |
| BOC Sciences | +1-631-485-4226 | inquiry@bocsci.com | United States | 19936 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +17819995354 | marketing@targetmol.com | United States | 32466 | 58 |
| Hubei Ipure Biology Co., Ltd | +8613367258412 | ada@ipurechemical.com | China | 10236 | 58 |
| HONG KONG IPURE BIOLOGY CO.,LIMITED | 86 18062405514 18062405514 | ada@ipurechemical.com | CHINA | 3461 | 58 |
| Shaanxi Dideu Medichem Co. Ltd | +86-29-81139210 +86-17392587031 | 1059@dideu.com | China | 9996 | 58 |
| RongNa Biotechnology Co.,Ltd | +86-86-13583358881 +8618560316533 | Brad@rongnabiotech.com | China | 3373 | 58 |
| AFINE CHEMICALS LIMITED | +86-571-85134551 | info@afinechem.com | China | 15079 | 58 |
Related articles
- Bevacizumab: Introduction, uses, and Side effects
- Bevacizumab is an anti-angiogenic agent rationally designed to target vascular endothelial growth factor (VEGF), a key mediato....
- Apr 11，2024
View Lastest Price from Bevacizumab manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-07-26 | Avastin
216974-75-3
|
0.99 | RongNa Biotechnology Co.,Ltd | ||||
 |
2026-07-24 | Bevacizumab
216974-75-3
|
1G | 98%min | 30kg/month | WUHAN FORTUNA CHEMICAL CO., LTD | ||
 |
2026-06-30 | Bevacizumab
216974-75-3
|
1KG | 98% | 1000kg | Shaanxi Dideu New Materials Co. Ltd |
-
- Avastin
216974-75-3
- 0.99
- RongNa Biotechnology Co.,Ltd
-
- Bevacizumab
216974-75-3
- $0.00
- 98%min
- WUHAN FORTUNA CHEMICAL CO., LTD
-
- Bevacizumab
216974-75-3
- $0.00
- 98%
- Shaanxi Dideu New Materials Co. Ltd
